Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 63187-259

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 63187-259). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Rabeprazole Sodium Delayed Release Tablets 1)

Chemical structure of Rabeprazole Sodium, showing its molecular connectivity including a benzene ring linked to a sulfoxide group and a pyridine ring, with sodium and methoxyethoxy substituents.*

FDA Label Image

Figure 2 (Rabeprazole Sodium Delayed Release Tablets 2)

A line graph showing mean heartburn scores over a 28-day study period for three groups: placebo (n=68), rabeprazole 10 mg (n=64), and rabeprazole 20 mg (n=67). The y-axis represents mean score severity from 0 (none) to 4 (very severe), and the x-axis displays study days from -14 to 28. The graph shows decreasing heartburn severity after day 0 for the rabeprazole groups compared to placebo.*

FDA Label Image

Figure 3 (Rabeprazole Sodium Delayed Release Tablets 3)

A line graph showing mean heartburn scores over a 28-day study period comparing placebo, Rabeprazole Sodium 10 mg, and 20 mg delayed-release tablets. The graph plots mean scores on the y-axis against study days on the x-axis, illustrating score trends before and after treatment initiation (day 0).*

FDA Label Image

Figure 4 (Rabeprazole Sodium Delayed Release Tablets 4)

A line graph comparing mean heartburn scores over study days between placebo and Rabeprazole Sodium 20 mg groups. The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores from 0 (none) to 4 (very severe). Rabeprazole 20 mg shows a decrease in heartburn scores after day 0 compared to placebo.*

FDA Label Image

Figure 5 (Rabeprazole Sodium Delayed Release Tablets 5)

A line graph depicting mean heartburn scores over a 28-day study period comparing Rabeprazole Sodium 20 mg and placebo. The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores ranging from 0 (none) to 4 (very severe). Rabeprazole group scores decline more over time compared to placebo.*

FDA Label Image

63187-259-30 (Rabeprazole Sodium Delayed Release Tablets 6)

Label for Rabeprazole Sodium 20mg delayed-release tablets by Proficient Rx LP. The label states 30 tablets per package with each tablet containing 20mg rabeprazole sodium. Tablets are blue and enteric-coated, round, debossed with "KU" on one side and "7" on the other. Packaged by Proficient Rx LP, Thousand Oaks, CA and distributed by Lannett Company, Philadelphia, PA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.